Leukemia and Lymphoma

A recent study found that microbiome-based biomarkers may be useful in predicting patient responses to CAR T-cell therapy for non-Hodgkin lymphoma.

Members of the Association of Community Cancer Centers (ACCC) Alternative Payment Coalition discussed strategies for succeeding in value-based care and voiced concerns surrounding the upcoming Enhancing Oncology Model (EOM) during a panel discussion at the ACCC 2023 Annual Meeting and Business Summit.

Lee Greenberger, PhD, chief scientific officer of the Leukemia and Lymphoma Society, discusses how the pandemic changed clinical trial enrollment in the leukemia/lymphoma space.

Children with acute lymphoblastic leukemia living in US-Mexico border regions had worse 5-year survival rates compared with children living in other parts of Texas, a recent study found.

Lee Greenberger, PhD, chief scientific officer of the Leukemia and Lymphoma Society, discusses common questions that patients with leukemia and lymphoma ask about COVID-19 and vaccination.

In this interview, Lee Greenberger, PhD, chief scientific officer of the Leukemia and Lymphoma Society, discusses key takeaways from using social media to grow a leukemia and lymphoma registry.

Roy Beveridge, MD, and Brian Koffman, MD, explore how the Bruton tyrosine kinase inhibitors (BTKi) fit into value-based care models for oncology and the patient support offered to aid patients in gaining access to BTKis.

Brian Koffman, MD, and Roy Beveridge, MD, discuss the financial burdens of Bruton tyrosine kinase inhibitor therapy and considerations for oral therapy vs infusion therapy.

The phase 3 PhALLCON study found ponatinib plus chemotherapy more effective than imatinib with chemotherapy in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

While treatment with allogeneic hematopoietic cell transplantation (allo-HCT) showed improved disease-free survival compared with conventional consolidation chemotherapy, the findings suggest there may not be an overall survival (OS) benefit with allo-HCT for patients with intermediate-risk acute myeloid leukemia (AML) during first complete remission.

Coverage from the 64th Annual American Society of Hematology Meeting and Exposition, December 10-13, 2022, New Orleans, Louisiana.

Despite overall improvements in survival outcomes in recent decades, disparities in survival outcomes persist among children and young adults with acute lymphocytic leukemia (ALL) across racial and ethnic groups.

New data from the POLARIX STUDY show that substituting polatuzumab vedotin for 1 part of a classic first-line chemotherapy combination to manage diffuse large B-cell lymphoma improved progression-free survival without compromising health-related quality-of-life.

Results presented during the 64th American Society of Hematology Annual Meeting and Exposition could offer an effective option for those with relapsed or refractory DLBCL, even as chimeric antigen receptor T-cell therapy becomes standard of care for many patients.

In abstracts presented at the 64th American Society of Hematology Annual Meeting and Exposition, the investigational BTK inhibitor pirtobrutinib showed promising efficacy and safety in several types of B-cell lymphoma.

A recent study aggregated RNA sequencing data from more than 3000 samples to create a user-friendly database of transcription profiles in leukemia and related cell lines.

The broad approval, while expected, will likely signal a milestone in the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

The study authors said the method also has the advantages of having a quick turnaround and a relatively low cost.

The case is believed to be just the second reported in the scientific literature.

Research presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition examined how certain patient and demographic characteristics that may be related to socioeconomic disparities impact the risk of hematological cancers; the influence of diabetes on chronic myeloid leukemia; and 2 updates on ponatinib.

Two abstracts reviewed venetoclax, the first FDA-approved BCL-2 inhibitor in acute myeloid leukemia (AML) and a novel BCL-2 inhibitor to treat chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

The approval makes mosunetuzumab the first in its class approved to treat follicular lymphoma and comes shortly after data from a phase 2 trial was presented at the annual meeting of the American Society of Hematology.

The top 5 most-read content in leukemia and lymphoma for 2022 addressed chimeric antigen receptor T-cell therapy, updates in recommended treatment, and President Joe Biden’s announcement on the return of the Cancer Moonshot.

The top news out of the annual meeting of the American Society of Clinical Oncology (ASCO) highlighted findings in gliobastoma, HER2-low breast cancer, and Hodgkin lymphoma.